|
1
|
Huang XR, Chen WY, Truong LD and Lan HY:
Chymase is upregulated in diabetic nephropathy: Implications for an
alternative pathway of angiotensin II-mediated diabetic renal and
vascular disease. J Am Soc Nephrol. 14:1738–1747. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan YY, Nishiyama A, Fujisawa Y, Kobori H,
Nakano D, Matsuura J, Hase N, Hitomi H, Kiyomoto H, Urata H and
Kohno M: Contribution of chymase-dependent angiotensin II formation
to the progression of tubulointerstitial fibrosis in obstructed
kidneys in hamsters. J Pharmacol Sci. 111:82–90. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Urata H, Kinoshita A, Misono KS, Bumpus FM
and Husain A: Identification of a highly specific chymase as the
major angiotensin II-forming enzyme in the human heart. J Biol
Chem. 265:22348–22357. 1990.PubMed/NCBI
|
|
4
|
Miyazaki M and Takai S: Tissue angiotensin
II generating system by angiotensin-converting enzyme and chymase.
J Pharmacol Sci. 100:391–397. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takai S, Sakonjo H, Fukuda K, Jin D,
Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y and Miyazaki M: A
novel chymase inhibitor,
2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[,4-dioxo-1-phenyl-7-(2-pyridyloxy)]
2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after
balloon injury. J Pharmacol Exp Ther. 304:841–844. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Okamoto Y, Takai S and Miyazaki M: Effect
of chymase-dependent transforming growth factor beta on peritoneal
adhesion formation in a rat model. Surg Today. 34:865–867. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oleksyszyn J and Powers JC: Irreversible
inhibition of serine proteases by peptide derivatives of
(alpha-aminoalkyl) phosphonate diphenyl esters. Biochemistry.
30:485–493. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takai S, Yuda A, Jin D, Nishimoto M,
Sakagichi M, Sasaki S and Miyazaki M: Inhibition of chymase reduces
vascular proliferation in dog grafted veins. FEBS Lett.
467:141–144. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ninichuk V, Khandoga AG, Segerer S,
Loetscher P, Schlapbach A, Revesz L, Feifel R, Khandoga A, Krombach
F, Nelson PJ, et al: The role of interstitial macrophages in
nephropathy of type 2 diabetic db/db mice. Am J Pathol.
170:1267–1276. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cristovam PC, Carmona AK, Arnoni CP,
Maquigussa E, Pereira LG and Boim MA: Role of chymase in diabetic
nephrology. Exp Biol Med (Maywood). 237:985–992. 2012. View Article : Google Scholar
|
|
11
|
Uehara Y, Urata H, Ideishi M, Arakawa K
and Saku K: Chymase inhibition suppresses high-cholesterol
diet-induced lipid accumulation in the hamster aorta. Cardiovasc
Res. 55:870–876. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kovanen PT: Mast cells: Multipotent local
effector cells in atherothrombosis. Immunol Rev. 217:105–122. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ruiz-Torres MP, López-Ongil S, Griera M,
Díez-Marqués ML, Rodríguez-Puyol M and Rodríguez-Puyol D: The
accumulation of extracellular matrix in the kidney: Consequences on
cellular function. J Nephrol. 18:334–340. 2005.PubMed/NCBI
|
|
14
|
Leskinen MJ, Lindstedt KA, Wang Y and
Kovanen PT: Mast cell chymase induces smooth muscle cell apoptosis
by a mechanism involving fibronectin degradation and disruption of
focal adhesions. Arterioscler Thromb Vasc Biol. 23:238–243. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanemitsu H, Takai S, Tsuneyoshi H,
Nishina T, Yoshikawa K, Miyazaki M, Ikeda T and Komeda M: Chymase
inhibition prevents cardiac fibrosis and dysfunction after
myocardial infarction in rats. Hypertens Res. 29:57–64. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maeda Y, Inoguchi T, Takei R, Sawada F,
Sasaki S, Fujii M, Kobayashi K, Urata H, Nishiyama A and Takayanagi
R: Inhibition of chymase protects against diabetes-induced
oxidative stress and renal dysfunction in hamsters. Am J Physiol
Renal Physiol. 299:F1328–F1338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simon M, Röckl W, Hornig C, Gröne EF,
Theis H, Weich HA, Fuchs E, Yayon A and Gröne HJ: Receptors of
vascular endothelial growth factor/vascular permeability factor
(VEGF/VPF) in fetal and adult human kidney: Localization and
[125I]VEGF binding sites. J Am Soc Nephrol. 9:1032–1044.
1998.PubMed/NCBI
|
|
18
|
Kang DH, Joly AH, Oh SW, Hugo C,
Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen
KM, et al: Impaired angiogenesis in the remnant kidney model: I.
Potential role of vascular endothelial growth factor and
thrombospondin-1. J Am Soc Nephrol. 12:1434–1447. 2001.PubMed/NCBI
|
|
19
|
Tsuchida K, Makita Z, Yamagishi S, Atsumi
T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K and Koike
T: Suppression of transforming growth factor beta and vascular
endothelial growth factor in diabetic nephropathy in rats by a
novel advanced glycation end product inhibitor, OPB-9195.
Diabetologia. 42:579–588. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY,
Kim HK and Won NH: Role of vascular endothelial growth factor in
diabetic nephropathy. Kidney Int Suppl. 77:S104–S112. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de Vriese AS, Tilton RG, Elger M, Stephan
CC, Kriz W and Lameire NH: Antibodies against vascular endothelial
growth factor improve early renal dysfunction in experimental
diabetes. J Am Soc Nephrol. 12:993–1000. 2001.PubMed/NCBI
|
|
22
|
Schrijvers BF, Flyvbjerg A, Tilton RG,
Lameire NH and De Vriese AS: A neutralizing VEGF antibody prevents
glomerular hypertrophy in a model of obese type 2 diabetes, the
Zucker diabetic fatty rat. Nephrol Dial Transplant. 21:324–329.
2006. View Article : Google Scholar
|
|
23
|
Cooper ME, Vranes D, Youssef S, Stacker
SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ and Gilbert
RE: Increased renal expression of vascular endothelial growth
factor (VEGF) and its receptor VEGFR-2 in experimental diabetes.
Diabetes. 48:2229–2239. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hovind P, Tarnow L, Oestergaard PB and
Parving HH: Elevated vascular endothelial growth factor in type 1
diabetic patients with diabetic nephropathy. Kidney Int Suppl.
75:S56–S61. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Katada J, Muramatsu M, Hayashi I, Tsutsumi
M, Konishi Y and Majima M: Significance of vascular endothelial
cell growth factor upregulation mediated via a
chymase-angiotensin-dependent pathway during angiogenesis in
hamster sponge granulomas. J Pharmacol Exp Ther. 302:949–956. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eremina V, Sood M, Haigh J, Nagy A, Lajoie
G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH and Quaggin SE:
Glomerular-specific alterations of VEGF-A expression lead to
distinct congenital and acquired renal diseases. J Clin Invest.
111:707–716. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang L, Kwak JH, Kim SI, He Y and Choi ME:
Transforming growth factor-beta1 stimulates vascular endothelial
growth factor 164 via mitogen-activated protein kinase kinase
3-p38alpha and p38delta mitogen-activated protein kinase-dependent
pathway in murine mesangial cells. J Biol Chem. 279:33213–33219.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Hu J, Zhang Q, Sun X and Li S:
Urocortin 1 improves renal function in rats with
streptozotocin-induced diabetes by inhibiting overproduction of
TGF-beta 1 and VEGF. Br J Pharmacol. 157:994–1003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takai S, Jin D and Miyazaki M: Multiple
mechanisms for the action of chymase inhibitors. J Pharmacol Sci.
118:311–316. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khera TK, Martin J, Riley SG, Steadman R
and Phillips AO: Glucose modulates handling of apoptotic cells by
mesangial cells: Involvement of TGF-beta1. Lab Invest. 87:690–701.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Umezono T, Toyoda M, Kato M, Miyauchi M,
Kimura M, Maruyama M, Honma M, Yagame M and Suzuki D: Glomerular
expression of CTGF, TGF-beta 1 and type IV collagen in diabetic
nephropathy. J Nephrol. 19:751–757. 2006.PubMed/NCBI
|
|
32
|
Grande JP, Warner GM, Walker HJ, Yusufi
AN, Cheng J, Gray CE, Kopp JB and Nath KA: TGF-beta1 is an
autocrine mediator of renal tubular epithelial cell growth and
collagen IV production. Exp Biol Med (Maywood). 227:171–181.
2002.
|
|
33
|
Shankland SJ, Scholey JW, Ly H and Thai K:
Expression of transforming growth factor-beta 1 during diabetic
renal hypertrophy. Kidney Int. 46:430–442. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Geng H, Lan R, Wang G, Siddiqi AR, Naski
MC, Brooks AI, Barnes JL, Saikumar P, Weinberg JM and Venkatachalam
MA: Inhibition of autoregulated TGF-beta signaling simultaneously
enhances proliferation and differentiation of kidney epithelium and
promotes repair following renal ischemia. Am J Pathol.
174:1291–1308. 2009. View Article : Google Scholar : PubMed/NCBI
|
